Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2018-06-22 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于部分股票期权注销完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of cancellation of certain stock options under the company's 2017 stock option incentive plan. It details the background of the stock option plan, approvals by the board and supervisory committee, and the specifics of the cancellation of 180,000 stock options due to employees leaving the company. The document is relatively short (1808 characters) and focuses on a corporate action related to stock options, not a full financial report or detailed management discussion. It is not an annual or interim report, earnings release, or audit report. It is also not a regulatory filing or certification. The content fits best with a Capital/Financing Update (CAP) as it relates to changes in the company's capital structure through stock option cancellations, which is a financing-related corporate action.
2018-06-22 Chinese
关于部分理财产品到期赎回的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhuhai Jianfan Biotechnology Co., Ltd. regarding the progress of redemption of certain financial products. It details the use of idle funds and raised funds for cash management investments, including specific financial products purchased, their redemption status, yields, and risk management measures. The document references prior shareholder meeting resolutions and previous announcements but does not contain comprehensive financial statements or detailed financial performance data. It is a regulatory disclosure about the company's cash management activities and investment risks, typical of a regulatory announcement rather than a full financial report or earnings release. The document length is about 4949 characters, which is relatively short and focused on a specific topic rather than a broad financial report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-06-19 Chinese
国浩律师（深圳）事务所关于公司调整2017年股票期权激励计划首次授予期权行权价格之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment of the exercise price of stock options under the company's 2017 stock option incentive plan. It discusses legal compliance, approvals, and the calculation method for the price adjustment due to dividend distribution. The document is not a financial report, earnings release, or management discussion but a legal opinion related to a capital/financing matter (stock option plan adjustment). It is not a simple announcement but a detailed legal opinion letter. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 4016 characters, which is sufficient for a detailed legal opinion rather than a brief announcement.
2018-06-11 Chinese
关于回购注销部分限制性股票的公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the company's repurchase and cancellation of part of its restricted stock under a 2016 restricted stock incentive plan. It includes descriptions of board and shareholder meetings approving the repurchase, the number of shares involved, changes in share capital structure, and legal opinions. The content focuses on a capital structure change due to share repurchase and cancellation of restricted shares. It is not a full financial report, earnings release, or management discussion. It is not a simple announcement of a report publication but a substantive disclosure about share repurchase and capital change. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as share repurchases and cancellations.
2018-06-11 Chinese
关于调整2016年限制性股票激励计划回购价格的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhuhai Jianfan Biotechnology Co., Ltd. regarding the adjustment of the repurchase price of the 2016 restricted stock incentive plan. It details board and supervisory meetings, approvals, legal opinions, and the rationale for adjusting the repurchase price due to dividend distribution. The document is a formal announcement about a change in the stock incentive plan's repurchase price, not a full report or financial statement. It is not an annual report, audit report, earnings release, or management report. It is also not a proxy solicitation or voting result announcement. The content fits best with a Regulatory Filing (RNS) as it is a regulatory announcement about a corporate action related to stock incentives and repurchase price adjustments, without substantive financial statements or detailed financial analysis. The document length is 3575 characters, which is relatively short and consistent with an announcement rather than a full report.
2018-06-11 Chinese
国浩律师（深圳）事务所关于公司注销部分股票期权之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain stock options of Zhuhai Jianfan Biotechnology Co., Ltd. It discusses the legal basis, approvals, and authorizations related to the cancellation of stock options under the company's 2017 stock option incentive plan. The document is not a financial report, earnings release, or regulatory filing about financial results or corporate governance changes. It is a standalone legal opinion related to a specific corporate action (cancellation of stock options). This fits best under the category of Regulatory Filings (RNS) as it is a legal opinion document that does not fit into other more specific categories such as Capital/Financing Update or Director's Dealing. The document length is under 5,000 characters, but it is a full legal opinion, not just an announcement of a report, so it is not RPA. Therefore, the best classification is Regulatory Filings (RNS).
2018-06-11 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.